This is a scientific publication announcement with no immediate catalyst for the stock. The company explicitly ruled out pursuing liver cancer as an indication, limiting the direct read-through. Monitor for partnership discussions or clinical data readouts in the company's focus areas (pancreatic, colorectal, anal cancer) for real catalysts.
Price Chart
Executive Summary
Oncolytics Biotech announced a publication in the Proceedings of the National Academy of Sciences showing that its investigational immunotherapy, pelareorep, can convert immunologically 'cold' liver tumors (hepatocellular carcinoma) into 'hot' tumors that may respond to immune-based therapies. The company explicitly stated it does not intend to pursue liver cancer as an indication, but views the data as supportive of its broader narrative that pelareorep can serve as a backbone immunotherapy across challenging tumor types. This is a preclinical, non-clinical data disclosure with no financial figures, no new clinical trial results, and no change to the company's stated development plans.
Key Facts
- Preclinical data published in PNAS on September 28, 2026, demonstrate pelareorep's ability to shift the tumor microenvironment from immunologically inactive to active in hepatocellular carcinoma.
- Company CMO stated liver cancer is not an indication the company intends to pursue at this time.
- No financial data, no new clinical trial results, no regulatory milestones, and no changes to guidance or development timelines were disclosed.
- The press release is furnished (not filed) under Item 8.01, indicating it is not deemed to contain material financial information.
Financial Impact
No financial impact disclosed. The filing contains no revenue, earnings, deal values, or other financial metrics.
Risk Factors
- Preclinical data may not translate to clinical efficacy in humans.
- Company explicitly stated it will not pursue liver cancer, so this data has limited direct commercial value.
- No timeline or financial commitment to advance this specific finding was provided.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000059 |
| Document: pnashccpublication.htm | 0001129928-26-000059 |
| Document: 0001129928-26-000059-index-headers.html | 0001129928-26-000059 |
| Document: 0001129928-26-000059-index.html | 0001129928-26-000059 |
| Document: 0001129928-26-000059.txt | 0001129928-26-000059 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $0.4986 | awaiting T+20 | — | $0.5000 (+0.28%) |
Oct 20, 2026 6d ago | Press Release | $0.4986 | awaiting T+20 | — | $0.5000 (+0.28%) |
Oct 14, 2026 12d ago | 8-K | $0.5382 | awaiting T+20 | — | $0.5000 (−7.10%) |
Oct 13, 2026 13d ago | 8-K | $0.4900 | awaiting T+20 | — | $0.5000 (+2.04%) |
Oct 6, 2026 20d ago | DEFA14A | $0.6000 | awaiting T+20 | — | $0.5000 (−16.67%) |
Oct 6, 2026 20d ago | DEF 14A | $0.6000 | awaiting T+20 | — | $0.5000 (−16.67%) |
Sep 29, 2026 27d ago | 8-K | $0.6745 | awaiting T+20 | — | $0.5000 (−25.87%) |
Sep 28, 2026 28d ago | 8-K | $0.6630 $0.4732 | ▼ −28.63% | ▼ −28.60% | $0.5000 (−24.59%) |
Sep 10, 2026 6w ago | 8-K | $0.7720 $0.5444 | ▼ −29.48% | ▼ −31.61% | $0.5000 (−35.23%) |
Jul 20, 2026 14w ago | 8-K | $0.8500 $0.8227 | ▼ −3.21% | ▼ −7.33% | $0.5000 (−41.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers